Seeking Alpha

Akorn (AKRX +2%) makes new 52-week highs after Deutsche reiterates a Buy on the drug developer....

Akorn (AKRX +2%) makes new 52-week highs after Deutsche reiterates a Buy on the drug developer. The firm is lifting its estimates following Akorn's acquisition of 3 injectable products, and claims the company's pipeline, expansion efforts, and growth opportunities leave it well-positioned to deliver 30%+ EPS growth over the next 3 years. It also believes Akorn is a potential takeover candidate.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|